Vinay Prasad Returns to the FDA With Fewer Titles and a Lower Profile

Vinay Prasad is returning to the FDA just weeks after his ouster, resuming leadership of the Center for Biologics Evaluation and Research (CBER)135.

He will again oversee regulation of vaccines, gene therapy, and blood products but it is unclear if he will hold additional high-profile positions such as chief medical and scientific officer13.

Prasad’s earlier departure was linked to escalating tensions over the FDA's handling of a gene therapy for Duchenne muscular dystrophy and external political pressure1.

His return appears to come with fewer official titles, indicating a potentially reduced influence or a lower profile within the agency compared to his previous tenure13.

Sources:

1. https://www.statnews.com/2025/08/09/vinay-prasad-returns-to-the-fda-weeks-after-his-ouster/

3. https://www.fiercepharma.com/pharma/vinay-prasad-back-fda-after-surprise-ouster-will-he-stay-time

5. https://www.raps.org/news-and-articles/news-articles/2025/8/recon-prasad-returns-fda-as-cber-chief;-fda-grants